FRIDAY, Feb. 24 (HealthDay News) -- The first generic version of the brand name drug Flonase was approved Feb. 22 by the U.S. Food and Drug Administration. Manufactured by Roxane Laboratories of Columbus, Ohio, Fluticasone Propionate Nasal Spray treats the nasal symptoms of seasonal and chronic allergic and non-allergic rhinitis. The FDA approved its use for adults and children ages 4 and older.
Fluticasone Propionate Nasal Spray contains a synthetic, trifluorinated corticosteroid with anti-inflammatory activity. Although it does not usually have an immediate effect on allergic symptoms, some patients experience a decrease in stuffiness, runniness, itching and sneezing 12 hours after initial treatment. Headache, sore throat and nose bleed are the most common side effects.
GlaxoSmithKline's Flonase received FDA approval in October 1994. Flonase's patent, including pediatric exclusivity, expired in May 2004 and a dosing schedule exclusivity associated with the pediatric exclusivity expired on Nov. 23, 2005.
More Information
